2022-10-21

ROI-NJ: BD’s new Onclarity HPV test greatly improves standard of care for women

ROI-NJ: BD’s new Onclarity HPV test greatly improves standard of care for women

Molly Broache, Associate Director, Medical Affairs for US IDS explains how the BD Onclarity™ HPV Assay positively impacts public health by providing a more precise estimate of a woman’s risk of cervical precancer and cancer.

Latest resources

Discover our latest articles, webinars, press releases and updates in women's health.

BD Onclarity™ HPV Assay with extended genotyping
Cervical Cancer | Brochures
BD Onclarity™ HPV Assay with extended genotyping
FiercePharma
New BD survey finds nearly half of women unaware of STI treatment options
smiling woman
Cervical Cancer | News & Updates
Press Release: Women in U.S. can now collect their own sample for cervical cancer screening